Q/C Technologies amends terms of its Series G and H preferred shares and warrants with PharmaCyte
Q/C Technologies amended the terms governing its Series G and H preferred shares and certain warrants through an agreement with PharmaCyte Biotech, which holds the majority of the preferred shares of both series. The changes revise amendment procedures and beneficial ownership limits. Separately, PharmaCyte consented to extend the maturity of the Series H preferred shares from March 2, 2027 to September 2, 2027. The transaction was disclosed to the SEC in a Form 8-K on November 20, 2026.
In 35 seconds
- Q/C Technologies and PharmaCyte agreed to amend the terms of the Series G and H preferred shares and certain warrants.
- The agreement revises amendment procedures and beneficial ownership limits.
- PharmaCyte consented to extend the Series H preferred maturity from March 2 to September 2, 2027.
IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.